Reported 23 days ago
Morgan Stanley analysts predict significant growth for two stocks, Tenaya Therapeutics (TNYA) and Royalty Pharma (RPRX), with potential upsides of 670% and 88% respectively. TNYA focuses on innovative treatments for heart diseases, with promising clinical trials underway, while RPRX thrives in the biotech sector by acquiring royalty rights to various drugs. Both stocks have a unanimous 'Strong Buy' rating from analysts, indicating strong investor interest as the market remains bullish leading up to the 2024 elections.
Source: YAHOO